Tarsus Pharmaceuticals, Inc.

US$68.60As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:TARSHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR 22.28%
Div yield —
ROE (319.84%)
Biotechnology
Beta (5Y) 0.33
PE TTM —
TSR TTM (0.31%)
Mkt cap US$3.382B
ROIC (13.41%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$69
0.04%
(23.18%)
Hold 11|2|8|0|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.87
0.95
1.00
1.11
23.09%
41.55%
43.22%
42.45%
Revenue$M
199.3
210.2
213.4
207.5
14.85%
15.30%
15.88%
7.75%
Peers (US$3.382B)
Cap (US$)
PE
3.268B
—
3.366B
38.24x
Capital
TTM
5Y
10Y
Leveragex
1.639
0.027
0.027
EBIT/Intx
0.314
0.472
0.468
Own earn%
10.99
(79.24)
(78.12)
Sh yield%
39.25
13.95
14.97
Owners
Insiders/Inst%
1.73
22.48
Short interest%
2.40
SBC / revenue%
1.48
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
0–9
$1 testx
0.3
Incr. ROIC%
6